Clinical Trial Search

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Composite Progression-free Survival (cPFS) — 4.1; 6.7 months

Primary: Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6) — 25.0 percentage of participants

Primary: Progression Free Survival (PFS) — 2.6; 1.7 months

Primary: The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6 — 2.37; 2.82; 2.86 units on a scale

Primary: Part A: Pharmacokinetics - Dose-Normalized Area Under the Concentration Versus Time Curve of Paclitaxel From Time Zero to Infinity [AUC(0-∞)] in Cycle 1 — 29…

Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 5.1 percentage of participants

Primary: Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment — 0.09; -0.43; -0.48; -0.63 percentage of HbA1c — p=<0.0001

Primary: Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. — 55; 55…

Primary: Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants — 3.9132 milliseconds (msec) — p=0.0161

Primary: Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-∞)] Following a Single Dose in Cycle 1…

Primary: Change From Baseline in HbA1c After 12 Weeks of Treatment. — 0.30; -0.42; -0.40; -0.65 percentage of HbA1c — p=<0.0001

Primary: Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia — -19.6; -33.4…

Primary: Progression-Free Survival (PFS) — 11.5 months

Primary: The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)…